Last reviewed · How we verify
NCT06776419: RATIFY
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease
trial testing Cardiac Magnetic Ressonance Imaging in Fabry Disease in 54 participants. Currently enrolling.
1 December 2030
Quick facts
| Lead sponsor | Caroline Michaela Kistorp |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 1 May 2025 |
| Primary completion | 1 December 2030 |
| Estimated completion | 1 June 2031 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Cardiac Magnetic Ressonance Imaging
- 82Rubidium-positron emission tomography and computer-tomography
Conditions studied
- Fabry Disease — all drugs for Fabry Disease →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Caroline Michaela Kistorp
Who can join
18 and older, any sex, with Fabry Disease or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to investigate Fabry-related cardiomyopathy and the use of native T1-mapping, coronary microvascular function, cardiac inflammation, and cardiac injury in an effort to improve the ability to detect disease. The study aims to achieve this by: 1. Investigating the association between cardiac inflammation, fibrosis, and injury against the distribution and degree of microvascular disease in patients with Fabry disease with and without left ventricular hypertrophy (LVH) using cardiac magnetic resonance (CMR) imaging and 82Rubidium Positron emission tomography and computer tomography (82Rb-PET/CT). 2. Using an extensive, in-depth biomarker blood panel to investigate the pathological pathways associated with Fabry disease and Fabry-related cardiomyopathy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06776419
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Fabry Disease
Currently open trials in the same condition.
- NCT07187440 — A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease · recruiting
- NCT06539624 — Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease · NA · recruiting
- NCT07277361 — Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment · recruiting
- NCT06270316 — Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease · Phase 1, PHASE2 · recruiting
- NCT06325488 — Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease · recruiting
Other Caroline Michaela Kistorp trials
Trials by the same sponsor.
- NCT06325488 — Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease · recruiting
- NCT06303466 — Real World Evidence Study of Danish Fabry Patients · unknown
- NCT05599438 — Prospective, Longitudinal Study on FItness DOping in DenmarK · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06776419 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Caroline Michaela Kistorp
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06776419.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing